The Chief Executive Officer and founder of Turn Therapeutics is Bradley Burnam, who has led the enterprise through its developmental, regulatory, and commercialization milestones. With extensive experience navigating complex pharmaceutical frameworks and FDA approval pathways, he directs the company's strategic vision, scientific research initiatives, and proprietary drug delivery technology platform focused on advanced dermatology, wound care, and anti-infective therapeutic solutions.